Economic burden of amyotrophic lateral sclerosis in the United Kingdom

References

• Festoff BW. Amyotrophic lateral sclerosis. Current and future treatment strategies. Drugs 1996; 51: 28–44.
   PubMed Web of Science ®Google Scholar
• Munsat TL, Hollander D, Andres P, Finison L. Clinical trials in ALS: measurement and natural history. Adv Neurol 1991; 56: 515–519.
   PubMedGoogle Scholar
• Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Ann Neurol 1985; 18: 271–280.
   PubMed Web of Science ®Google Scholar
• Bach JR. Amyotrophic lateral sclerosis. Communication status and survival with ventilatory support. Am J Phys Med Rehabil 1993; 72: 343–349.
   PubMed Web of Science ®Google Scholar
• Moss AH, Casey P, Stocking CB et al. Home ventilation for amyotrophic lateral sclerosis patients. Outcomes, costs, and patient, family, and physician attitudes. Neurology 1993; 43: 438–443.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Risk factors in amyotrophic lateral sclerosis. Adv Neurol 1991; 56: 245–270.
   PubMedGoogle Scholar
• Norris F, Shepherd R, Denys E et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118: 48–55.
   PubMed Web of Science ®Google Scholar
• The Scottish Motor Neuron Disease Research Group. The Scottish motor neuron disease register: a prospective study of adult onset motor neuron disease in Scotland: Methodology, demography and clinical features of incident cases in 1989. J Neurol Neurosurg Psych 1992; 55: 536–541.
   PubMed Web of Science ®Google Scholar
• Tysnes OB, Vollset SE, Larsen JP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology 1994; 13: 226–235.
   PubMed Web of Science ®Google Scholar
• Hillel AD, Miller R. Bulbar amyotrophic lateral sclerosis: Patterns of progression and clinical management. Head Neck 1989; 11: 51–59.
   PubMed Web of Science ®Google Scholar
• Annegers JF, Appel S, Lee JRJ, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol 1991; 48: 589–593.
   PubMed Web of Science ®Google Scholar
• Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707–719.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF, Beebe GW. Epidemiology of amyotrophic lateral sclerosis: A case controlled comparison based on ALS deaths. Neurol 1980; 30: 453–462.
   PubMed Web of Science ®Google Scholar
• Durrleman S, Alperovitch A. Increasing trend of ALS in France and elsewhere: are the changes real? Neurol 1989; 39: 768–773.
   PubMed Web of Science ®Google Scholar
• Kahana E, Zilber N. Changes in the incidence of amyotrophic lateral sclerosis in Israel. Arch Neurol 1984; 41: 157–160.
   PubMedGoogle Scholar
• Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990-2040. Neuroepidemiology 1993; 12: 219–228.
   PubMedGoogle Scholar
• Drachman DB, Kuncl RW. Amytrophic lateral sclerosis: An unconventional autoimmune disease? Ann Neurol 1989; 26: 269–274.
   PubMedGoogle Scholar
• Wokke J. Riluzole. Lancet 1996; 348: 795–799.
   PubMed Web of Science ®Google Scholar
• Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci 1997; 18: 196–203.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. In: Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis, eds., G Serratrice & T. Munsat. Adv Neurol 1995; 68: 7–19.
   PubMedGoogle Scholar
• Bensimon G, Lacomblez L, Meininger V, and The ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN et al., for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425–1431.
   PubMed Web of Science ®Google Scholar
• Klein LM, Forshew DA. The economic impact of ALS. Neurol 1996; 47(Suppl 2)</b>: S126–S129.
   Google Scholar
• Moss AH, Oppenheimer EA, Casey P et al. Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning and outcomes. Chest 1996; 110: 249–255.
   PubMed Web of Science ®Google Scholar
• Ginsberg GM, Lev B. Cost-benefit analysis of riluzole for the treatment of Amyotrophic Lateral Sclerosis. Pharmacoeconomics 1997; 12: 578–584.
   PubMed Web of Science ®Google Scholar
• Rivière M, Meininger V, Zeisser P, Munsat TL. An analysis of extended survival in amyotrophic lateral sclerosis patients treated with riluzole. Arch Neurol. 1998; 55: 526–528.
   PubMed Web of Science ®Google Scholar
• Norris FH, Calanchini PR, Fallat RJ et al. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24: 721–728.
   Google Scholar
• Andres LA, Hedlund W, Finison L et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986; 36: 937–941.
   PubMed Web of Science ®Google Scholar
• Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings. Pharmacoeconomics 1997; 12: 121–129.
   PubMed Web of Science ®Google Scholar
• Netten A, Dennet J. Unit costs of health and social care. 1996; PSSRU, University of Kent.
   Google Scholar
• Smith & Nephew Rehabilitation Catalogue. Hull (UK), 1996.
   Google Scholar
• The Drug Tariff. HM Stationary Office, 1996.
   Google Scholar
• Chemist and Druggist. Miller Freeman, November 1996.
   Google Scholar
• Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sciences 1996; 139 (Suppl.): 123–128.
   Google Scholar
• Bach JR, Barnett V. Ethical considerations in the management of individuals with severe neuromuscular disorders. Am J Phys Med Rehabil. 1995; 74: S34–S40.
   Web of Science ®Google Scholar